Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDAP NASDAQ:HOOK NASDAQ:IRIX NASDAQ:RSLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEDAP TMS$1.30-6.9%$1.64$1.26▼$4.93$52.35M-0.0949,174 shs39,767 shsHOOKHOOKIPA Pharma$0.89-0.9%$1.27$0.72▼$5.66$10.89M0.93154,042 shs28,044 shsIRIXIRIDEX$1.28-3.0%$1.06$0.78▼$2.14$21.49M0.62191,987 shs49,855 shsRSLSReShape Lifesciences$2.49+2.0%$3.03$2.23▼$303.25$5.82M1.16474,706 shs68,543 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEDAP TMS-6.90%-6.90%-16.98%-41.29%-73.32%HOOKHOOKIPA Pharma-0.90%-3.80%-28.05%-33.96%-84.79%IRIXIRIDEX-3.03%-9.22%+40.63%+7.56%-36.32%RSLSReShape Lifesciences+2.05%+0.40%+2.89%-76.29%-99.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDAPEDAP TMS2.8183 of 5 stars3.25.00.00.00.01.70.6HOOKHOOKIPA Pharma3.0719 of 5 stars3.25.00.00.00.02.50.6IRIXIRIDEX0.4914 of 5 stars0.04.00.00.00.61.70.0RSLSReShape Lifesciences0.6707 of 5 stars0.04.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDAPEDAP TMS 2.33Hold$8.50552.14% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50408.47% UpsideIRIXIRIDEX 0.00N/AN/AN/ARSLSReShape Lifesciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RSLS, EDAP, HOOK, and IRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025EDAPEDAP TMSPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDAPEDAP TMS$69.18M0.70N/AN/A$1.18 per share1.10HOOKHOOKIPA Pharma$43.95M0.25N/AN/A$4.25 per share0.21IRIXIRIDEX$48.80M0.44N/AN/A$0.13 per share9.85RSLSReShape Lifesciences$8.01M0.74N/AN/A($8.66) per share-0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDAPEDAP TMS-$20.58M-$0.62N/AN/AN/A-34.45%-51.42%-26.43%8/27/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)IRIXIRIDEX-$8.91M-$0.43N/A∞N/A-14.61%-290.57%-22.86%8/12/2025 (Estimated)RSLSReShape Lifesciences-$7.13M-$193.23N/A∞N/A-48.26%-251.90%-59.49%8/13/2025 (Estimated)Latest RSLS, EDAP, HOOK, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/27/2025Q2 2025EDAPEDAP TMS-$0.18N/AN/AN/A$16.60 millionN/A8/14/2025Q2 2025HOOKHOOKIPA Pharma-$0.64N/AN/AN/AN/AN/A5/20/2025Q1 2025RSLSReShape LifesciencesN/A$18.98N/A$18.98N/A$1.11 million5/15/2025Q1 2025EDAPEDAP TMS-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDAPEDAP TMSN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ARSLSReShape LifesciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDAPEDAP TMS0.101.741.21HOOKHOOKIPA PharmaN/A3.613.61IRIXIRIDEX4.281.951.27RSLSReShape LifesciencesN/A1.530.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDAPEDAP TMS62.74%HOOKHOOKIPA Pharma63.88%IRIXIRIDEX20.10%RSLSReShape Lifesciences22.06%Insider OwnershipCompanyInsider OwnershipEDAPEDAP TMS0.23%HOOKHOOKIPA Pharma3.30%IRIXIRIDEX7.40%RSLSReShape Lifesciences0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDAPEDAP TMS23037.39 million37.31 millionOptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableIRIXIRIDEX12016.79 million15.55 millionOptionableRSLSReShape Lifesciences502.39 million2.39 millionNot OptionableRSLS, EDAP, HOOK, and IRIX HeadlinesRecent News About These CompaniesReShape Lifesciences Holds Special Stockholder MeetingJuly 25, 2025 | tipranks.comReShape Lifesciences® Announces Partial Adjournment of Special Meeting of StockholdersJuly 24, 2025 | globenewswire.comReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon SummitJuly 22, 2025 | globenewswire.comReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025July 21, 2025 | globenewswire.comReShape Lifesciences provides $200,000 loan to Vyome Therapeutics under merger terms - Investing.comJuly 5, 2025 | investing.comReShape Lifesciences Loans $200K to Vyome TherapeuticsJuly 3, 2025 | tipranks.comReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon SystemJuly 1, 2025 | globenewswire.comReShape Lifesciences Inc (RSLS) Stock Forums - Investing.comJune 28, 2025 | investing.comReShape Lifesciences Inc: ReShape Lifesciences Regains Compliance with Nasdaq Minimum Stockholders Equity RequirementJune 27, 2025 | finanznachrichten.deReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with ... - MorningstarJune 27, 2025 | morningstar.comMReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity RequirementJune 27, 2025 | globenewswire.comRSLS - Reshape Lifesciences Inc Executives - MorningstarJune 26, 2025 | morningstar.comMRSLS - Reshape Lifesciences Inc Valuation - MorningstarJune 26, 2025 | morningstar.comMReShape Lifesciences receives Australian patent for diabetes deviceJune 26, 2025 | investing.comReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad MedisysJune 26, 2025 | globenewswire.comReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation TechnologyJune 25, 2025 | globenewswire.comReShape Lifesciences Raises Equity to Avoid DelistingJune 18, 2025 | tipranks.comReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail ApplauseJune 13, 2025 | msn.comReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsJune 12, 2025 | finanznachrichten.deReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsJune 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRSLS, EDAP, HOOK, and IRIX Company DescriptionsEDAP TMS NASDAQ:EDAP$1.30 -0.10 (-6.90%) Closing price 08/1/2025 03:48 PM EasternExtended Trading$1.27 -0.04 (-2.87%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.HOOKIPA Pharma NASDAQ:HOOK$0.88 -0.01 (-0.90%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$0.88 0.00 (-0.45%) As of 08/1/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.IRIDEX NASDAQ:IRIX$1.28 -0.04 (-3.03%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.26 -0.02 (-1.56%) As of 08/1/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.ReShape Lifesciences NASDAQ:RSLS$2.49 +0.05 (+2.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.46 -0.03 (-1.16%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
